Welcome to our dedicated page for Rocket Pharmaceu SEC filings (Ticker: RCKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rocket Pharmaceuticals, Inc. (RCKT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, late-stage biotechnology company, Rocket uses SEC reports to communicate material information about its gene therapy pipeline, financial condition, governance and significant corporate events.
Investors can use this page to locate current reports on Form 8-K, which Rocket files to describe events such as financial results, strategic corporate reorganization and pipeline prioritization, clinical trial developments and regulatory milestones. Recent 8-K filings referenced in available information include announcements of quarterly financial results, FDA acceptance of the resubmitted Biologics License Application (BLA) for KRESLADI in severe leukocyte adhesion deficiency-I (LAD-I), lifting of the clinical hold on the pivotal Phase 2 trial of RP-A501 for Danon disease, and leadership or board changes.
In addition to 8-Ks, users can access Rocket’s periodic reports on Forms 10-K and 10-Q, which provide more detailed discussions of its AAV and lentiviral gene therapy programs, risk factors and financial statements. These filings help explain how Rocket is prioritizing its AAV cardiovascular platform—covering Danon disease, PKP2-arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy—while advancing regulatory activities for KRESLADI and pausing additional internal investment in certain other programs.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, such as clinical and regulatory updates, restructuring plans, and changes in executive leadership. Real-time EDGAR updates allow users to see new Rocket filings as they are posted, while Form 4 insider transaction data and proxy materials can be reviewed to understand equity awards, inducement grants and governance practices. This page serves as a focused entry point for analyzing how Rocket’s SEC disclosures relate to the development and potential commercialization of its rare disease gene therapy portfolio.
Rocket Pharmaceuticals shareholder Jonathan D. Schwartz has filed to sell 14,508 shares of common stock. The planned sale, through Fidelity Brokerage Services, has an aggregate market value of $48,051.95, with an approximate sale date of February 13, 2026 on NASDAQ.
The 14,508 shares were acquired on February 11, 2026 via restricted stock vesting from the issuer as compensation. Schwartz previously sold 2,545 common shares on November 18, 2025 for gross proceeds of $7,591.22. Shares outstanding were 108,222,228 at the time referenced.
John Militello filed a notice of proposed sale of 3,726 shares of common stock of issuer RCKT under Rule 144. The shares, with an aggregate market value of $12,340.88, are to be sold through Fidelity Brokerage Services LLC on NASDAQ, where 108,222,228 shares are outstanding.
The securities were acquired on 02/11/2026 through restricted stock vesting from the issuer as compensation. Militello previously sold 1,086 common shares for gross proceeds of $3,239.32 on 11/18/2025. By signing, he represents he is not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 8,544,423 shares of Rocket Pharmaceuticals common stock, representing 7.89% of the outstanding class.
Vanguard reports no sole voting or dispositive power, only shared authority over these shares, which are held for clients. It states the position is held in the ordinary course of business, not to change or influence control of Rocket Pharmaceuticals. Vanguard also notes an internal realignment, after which certain subsidiaries may report beneficial ownership separately while continuing the same investment strategies.
Rocket Pharmaceuticals director Elisabeth Bjork reported buying 10,000 shares of common stock on January 2, 2026 at $3.44 per share. After this purchase, she beneficially owned 50,000 shares in total.
The total includes 30,000 restricted stock units that convert into common stock on a one-for-one basis and are scheduled to vest in full on June 18, 2026. The filing indicates the shares are held directly rather than through another entity.
Rocket Pharmaceuticals insider trading update: A company officer reported a small sale of common stock. On 11/18/2025, the Chief Science & Gene Therapy Officer disposed of 2,545 shares of Rocket Pharmaceuticals, Inc. (RCKT) common stock at a price of $2.983 per share in an open market sale. After this transaction, the reporting person beneficially owns 299,064 shares, which include Restricted Stock Units that convert into common stock on a one-for-one basis.
Rocket Pharmaceuticals, Inc. (RCKT) officer John Militello reported a sale of 1,086 shares of common stock on November 18, 2025 at a price of $2.983 per share. After this transaction, he beneficially owns 65,920 shares, held directly. The holdings include restricted stock units (RSUs) that convert to common stock on a one-for-one basis. Militello is identified as Vice President of Finance, Treasurer and Principal Accounting Officer.
Rocket Pharmaceuticals, Inc. (RCKT) CEO and director Gaurav Shah reported an open-market sale of 6,276 shares of common stock on November 18, 2025 at a price of $2.983 per share.
Following this transaction, he beneficially owns 778,296 shares directly, 207,897 shares indirectly through his spouse, and 198,341 shares indirectly through the Gaurav D. Shah Irrevocable Trust. The reported holdings include Restricted Stock Units that convert into common stock on a one-for-one basis.
Rocket Pharmaceuticals, Inc. (RCKT) reported an insider stock transaction by its General Counsel, Martin Louis Wilson. On 11/18/2025, he sold 1,646 shares of Rocket Pharmaceuticals common stock at a price of $2.983 per share in a single transaction. After this sale, he beneficially owns 383,816 shares of Rocket Pharmaceuticals common stock in direct ownership. These holdings include Restricted Stock Units that convert to common stock on a one-for-one basis.
Rocket Pharmaceuticals (RCKT) reported an insider equity award. The company’s General Counsel acquired 100,000 shares on 11/03/2025 at a reported price of $0, identified as Restricted Stock Units that convert to common stock on a one-for-one basis and fully vest on 11/03/2026.
Following this transaction, the reporting person beneficially owned 385,462 shares, held directly. This filing reflects routine equity compensation rather than an open‑market purchase.
Rocket Pharmaceuticals (RCKT) filed its Q3 2025 10‑Q, reporting continued investment in late-stage gene therapies without revenue. Net loss was $50.3 million for the quarter and $180.6 million for the nine months ended September 30, 2025. Operating expenses declined year over year as R&D fell to $34.1 million from $42.3 million and G&A to $18.4 million from $27.1 million, reflecting portfolio reprioritization.
Cash, cash equivalents and investments totaled $222.8 million as of September 30, 2025, and the company expects this to fund operations into the second quarter of 2027. Stockholders’ equity was $313.7 million. Rocket implemented a strategic reorganization in July 2025, reducing its workforce by ~30% and recording $3.3 million in restructuring charges year to date.
In clinical updates, the FDA lifted the clinical hold on the RP‑A501 Phase 2 trial on August 20, 2025 after the company addressed issues outlined in the hold. A prior intellectual property dispute with Lexeo was settled with no material financial impact.